First Trust Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

First Trust Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,007,624	Closed	-$46.1M	–	2461
2017 Q4	$46.1M	Sell	1,007,624 -287,858	-22%	-$14.4M	0.11%	215
2017 Q3	$58.1M	Sell	1,295,482 -14,485	-1%	-$494K	0.15%	145
2017 Q2	$39.2M	Sell	1,309,967 -67,700	-5%	-$1.67M	0.1%	222
2017 Q1	$30.6M	Buy	1,377,667 +440,984	+47%	+$9.46M	0.08%	295
2016 Q4	$17.7M	Buy	936,683 +7,378	+0.8%	+$181K	0.05%	512
2016 Q3	$27.9M	Buy	929,305 +226,108	+32%	+$7.03M	0.08%	309
2016 Q2	$27M	Sell	703,197 -194,084	-22%	-$8.06M	0.09%	300
2016 Q1	$34.2M	Sell	897,281 -1,171,009	-57%	-$40.8M	0.11%	217
2015 Q4	$90.9M	Buy	+2,068,290	New	+$103M	0.24%	89

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

First Trust Advisors's JUNO Position: Q1 2018 in Review

First Trust Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 1,007,624 shares — an estimated $46.1M sold.

First Trust Advisors first reported a position in JUNO in Q4 2015 and held it in 9 quarters. The position peaked at $90.9M in Q4 2015. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

First Trust Advisors reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
First Trust Advisors sold 1,007,624 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $46.1M.
First Trust Advisors first reported a position in Juno Therapeutics, Inc. in Q4 2015 and held it in 9 quarters.
First Trust Advisors's Juno Therapeutics, Inc. position peaked at $90.9M in Q4 2015.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on First Trust Advisors's 13F filing for Q1 2018, filed 23 Apr 2018.